Takeda Looks To The New As It Braces For Velcade Generics
Takeda is facing major revenue challenges from US generics to its big seller Velcade, but is looking to successor and other new products to more than plug the gap.
You may also be interested in...
Takeda raises full-year forecast after "significant momentum" in the first half, driven by mainstays, cost savings and delayed US generic competition to Velcade.
Takeda and Shire are already discussing their planned integration across multiple areas, but until the deal closes formally the Japanese firm stresses it is business as usual, as it reports solid underlying growth in the fiscal first quarter, driven by core products.
New positive data with more convenient formulation set stage for increased Entyvio competitiveness in ulcerative colitis maintenance setting, while other early results bode well for Ninlaro in maintenance use in multiple myeloma.